SiRNA (small interfering ribonucleic acid) functionalized tetrahedral framework nucleic acid composite material as well as preparation method and application thereof

By assembling siRNA-NF-κB p65 with single-stranded DNA by functionalized tetrahedral framework nucleic acid (Tsi), enhancing cell membrane permeability and gene targeting specificity, solving the problem of regulation of NF-κB signaling pathway in temporomandibular arthritis. Effective silencing of NF-κBp65 and inhibition of inflammation are achieved, and cartilage repair is promoted, providing a more accurate therapeutic strategy.

CN118976117AInactive Publication Date: 2024-11-19SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411073214.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver and target the regulation of NF-κB signaling pathway, resulting in poor treatment of temporomandibular arthritis, and siRNA has limitations in stability and cell membrane penetration.

Method used

Develop a functionalized tetrahedral framework nucleic acid (Tsi) to form a base complementary pairing structure by assembling siRNA-NF-κB p65 with 4 single-stranded DNA, enhancing its cell membrane permeability and gene targeting specificity, and inhibiting NF- κBp65 expression activates Wnt/β-catenin and NRF2/HO-1 pathways to alleviate inflammation.

Benefits of technology

Tsi effectively downregulates NF-κBp65 expression, inhibits inflammation, promotes chondrocyte proliferation and repair, reduces cellular oxidative stress, significantly attenuates the occurrence of osteoarthritis, and provides a more accurate treatment strategy for temporomandibular arthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976117A_ABST
    Figure CN118976117A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a tetrahedral framework nucleic acid combined with siRNA related to a silent NF-kappa Bp65 gene as well as a preparation method and application of the tetrahedral framework nucleic acid. The invention combines the strong cell membrane permeability of tetrahedral framework nucleic acid and the gene targeting specificity of siRNA-NF-kappa Bp65, and provides a tetrahedral framework nucleic acid system combined with siRNA related to silent NF-kappa Bp65 gene, and the system can effectively and continuously down-regulate the expression of NF-kappa Bp65, so that the expression of the siRNA related to silent NF-kappa Bp65 can be effectively and continuously regulated by inhibiting Wnt / beta-catenin, and the expression of siRNA related to silent NF-kappa Bp65 can be effectively and continuously regulated. And the NRF2 / heme oxygenase-1 (HO-1) pathway is up-regulated to inhibit the joint inflammation and promote the repair of the articular cartilage. The delivery system provided by the invention has a more excellent treatment effect in treatment of temporomandibular arthritis, and is expected to become a new way for treatment of temporomandibular arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a siRNA functionalized tetrahedral framework nucleic acid composite material and a preparation method and application thereof. Background Art

[0002] Among the temporomandibular joint (TMJ) diseases, TMJ is one of the most common degenerative diseases, with a high male-female ratio (2:1), accounting for about 5-12% of the global population. It is characterized by the occurrence of inflammation, cartilage degradation, changes in subchondral bone remodeling, chronic joint pain, and dysfunction. Ideally, successful treatment of TMJ should not only reduce or eliminate joint pain, but also delay or reverse the loss of condylar cartilage. In this regard, current treatments are not satisfactory. For example, taking nonsteroidal anti-inflammatory drugs (NSAIDs) and intra-articular injections of hyaluronic acid can reduce pain and inflammatory responses and improve quality of life, but these measures are not effective and are not targeted enough to prevent further development of inflammation. However, the recent rise of gene therapy provides a way to overcome this limitation. Among them, one of the target genes for TMJ treatment is nuclear factor κB (NF-κB).

[0003] The NF-κB signaling pathway is an important signaling pathway involved in regulating inflammatory responses, immune responses, cell proliferation, and other biological processes. Studies have shown that the NF-κB signaling pathway plays an important role in the pathogenesis of temporomandibular joint (TMJ) osteoarthritis and is a key initiating factor. NF-κB is a transcription factor involved in inflammation and immune activation, which is activated by oxidants and cytokines, such as IL-1β and TNF-α, which play an important role in the occurrence and development of OA. At the same time, the activation of the NF-κB signaling pathway can also promote the production of inflammatory factors such as MMP-1 and MMP-13, as well as the expression of inflammatory stimuli such as IL-1, IL-6, and TNF-α, which further aggravates the production of inflammatory factors. During the inflammatory process, the NF-κB signaling pathway overlaps with a variety of signaling pathways related to the development of the temporomandibular joint and crosstalks with each other. Therefore, targeted regulation of the NF-κB pathway may become a new strategy for the treatment of temporomandibular arthritis. However, the specific mechanism of action and efficacy of the NF-κB pathway in the treatment of temporomandibular arthritis still need further research and verification.

[0004] The RNA interference (RNAi) phenomenon was first discovered by Andrew Fire et al. in 1998. Small interfering RNA (siRNA) is a gene-targeted therapeutic tool with extremely high specificity and powerful efficacy. siRNA can induce RNAi silencing in mammalian cells without causing nonspecific interferon response. Together with Argonaute proteins, they form a cytoplasmic RNA-induced silencing complex (RNARISC). This silencing complex binds to the 3′ untranslated region of the siRNA-targeted mRNA, organizes the translation process of the target protein, and epigenetically regulates the gene of interest. After these siRNAs were discovered, they quickly became a popular tool in biological research. However, due to the limitations of siRNA itself, such as low targeting specificity, easy enzymatic degradation under physiological conditions, unstable structure, and inability to penetrate the cell membrane, the therapeutic potential of this method is still limited, and its clinical application is unclear.

[0005] Tetrahedral DNA nanostructures (tFNA) are a class of nucleic acid drugs that are self-assembled and synthesized based on the Watson-Crick base pairing rules to form a DNA nanostructure with a tetrahedral spatial shape. It is known for its excellent structural stability, resistance to enzyme degradation, and cell membrane permeability. It can carry various small molecule drugs, peptides, RNA, and metals to facilitate cargo transportation. In addition, tFNA itself has multiple biological functions both in vitro and in vivo, such as anti-inflammatory and antioxidant activity, and the ability to promote cell proliferation.

[0006] In summary, the use of siRNA related to silencing NF-κBp65 gene as a drug still has problems such as stability and cell membrane penetration. Therefore, the field urgently needs to develop a new drug system for delivering the siRNA. However, there is no literature report on the application of tFNA in siRNA. Summary of the invention

[0007] In view of the problems of the prior art, the present invention provides a tetrahedral framework nucleic acid combined with siRNA related to silencing NF-κBp65 gene, and a preparation method and use thereof.

[0008] A functionalized tetrahedral framework nucleic acid, characterized in that the functionalized tetrahedral framework nucleic acid is modified with siRNA-NF-κB p65.

[0009] Preferably, four single-stranded DNAs with sticky ends are combined with the sticky ends of siRNA-NF-κB p65 to form DNA-siRNA chains, and the four DNA-siRNA chains are assembled through complementary base pairing.

[0010] Preferably, the four single-stranded DNA nucleotide sequences are shown as SEQ ID NO.1-SEQ ID NO.4;

[0011] And / or, the sense strand of siRNA-NF-κB p65 is the nucleotide sequence shown in SEQ ID NO.5 having two deoxynucleotides at the 3' end.

[0012] The present invention also provides a method for preparing the functionalized tetrahedral framework nucleic acid, which is characterized by comprising the following steps: mixing siRNA-NF-κB p65 and four pre-designed single-stranded DNAs, and incubating them to obtain the functionalized tetrahedral framework nucleic acid.

[0013] The present invention also provides use of the functionalized tetrahedral framework nucleic acid in treating temporomandibular arthritis.

[0014] Preferably, the drug is used to protect chondrocytes;

[0015] Preferably, the drug is used to reduce cellular oxidative stress;

[0016] Preferably, the drug is used to promote cartilage matrix production;

[0017] Preferably, the drug is used to inhibit chondrocyte apoptosis, smooth cartilage surface, inhibit extracellular matrix degradation and increase synovial thickness to significantly reduce the occurrence of osteoarthritis.

[0018] The present invention also provides a medicine for treating temporomandibular arthritis, which is prepared by using the functionalized tetrahedral framework nucleic acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials.

[0019] In order to improve the current strategy for treating temporomandibular arthritis, the present invention designs a tetrahedral framework nucleic acid (TDN) system combined with siRNA related to silencing NF-κBp65 gene, called Tsi, which combines the strong cell membrane permeability of TDN and the gene targeting specificity of siRNA-NF-κBp65. Tsi effectively and continuously downregulates the expression of NF-κBp65, thereby inhibiting joint inflammation and promoting the repair of articular cartilage by inhibiting Wnt / β-catenin and upregulating the NRF2 / heme oxygenase-1 (HO-1) pathway, and more accurately treating temporomandibular arthritis.

[0020] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0021] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Synthesis and characterization of Tsi nanostructures. (A) Schematic diagram of the synthesis process of Tsi. (B) Verification of the stepwise loading process of Tsi. (C) Transmission electron microscopy (TEM) image of Tsi (scale bar, 50 nm; magnification: scale bar, 25 nm). (D) Atomic force microscopy (AFM) image (scale bar, 50 nm; magnification: scale bar, 25 nm). (E) Zeta potential of tFNA and Tsi. (F) Particle size of tFNA and Tsi. (G) Stability of Tsi in 2% FBS and lysis buffer at 37°C for 0, 2, 4, 6, 8, 10, 12, and 24 hours. (H, I) Flow cytometry was used to detect the uptake characteristics of siRNA, tFNA, and Tsi by chondrocytes after 12 and 24 hours of incubation. (J, K) The uptake characteristics of siRNA, tFNA and Tsi labeled with Cy5 in chondrocytes after 12 h and 24 h incubation were detected by confocal microscopy (red: Cy5; blue: nucleus; green: cytoskeleton. Scale bar: 20 μm).

[0023] Figure 2 (A) Scratch test to detect the effects of simple siRNA, tFNA and Tsi on the proliferation and migration of rat chondrocytes. Tsi has a good effect on promoting cell migration (scale bar: 200μm). (B) Protein expression levels of NF-κB p65, NF-κB p-p65, IκB-α, and β-catenin. Blot lanes: 1. Control group; 2. IL-1β group; 3. IL-1β+siRNA group (si); 4. IL-1β+TDN group (T); 5. IL-1β+Tsi group (Tsi).

[0024] Figure 3 Relative mRNA levels of NF-κB p65 at 1d and 3d after treatment with different conditions. Quantitative statistics of scratch test and CCK8 test. Quantitative analysis of apoptotic and necrotic chondrocytes after treatment with different conditions.

[0025] Figure 4 Flow cytometry was used to evaluate apoptotic chondrocytes under different treatment conditions.

[0026] Figure 5To quantitatively analyze the protein expression levels of NF-κB p65, NF-κB p-p65, IκB-α, and β-catenin in western blotting experiments.

[0027] Figure 6 It is the quantitative analysis of NF-κB p65, NF-κB p-p65, IκB-α, and β-catenin in cell immunofluorescence experiment.

[0028] Figure 7 Immunofluorescence staining images and three-dimensional statistical graphs of NF-κB p65, NF-κB p-p65, IκB-α, and β-catenin expression in chondrocytes after different treatments (red: detection protein; blue: cell nucleus; green: cytoskeleton. Scale bar: 20μm).

[0029] Figure 8 The protein expression levels of IL-1β, TNF-α, iNOS, NRF2, and HO-1. Blot lanes: 1. Control group; 2. IL-1β group; 3. IL-1β+siRNA group (si); 4. IL-1β+TDN group (T); 5. IL-1β+Tsi group (Tsi) and semi-quantitative analysis.

[0030] Fig. 9 Schematic diagram of Tsi silencing NF-κB in chondrocytes and acting on the wnt / β-catenin and Nrf2 / HO-1 pathways.

[0031] Fig.10 The ROS levels of chondrocytes treated with different methods were measured by fluorescence microscopy (blue: cell nucleus; green: ROS. Scale bar: 100 μm).

[0032] Fig.11 This is a heat map of relative mRNA expression of IL-1β, TNF-α, iNOS, NRF2, and HO-1.

[0033] Fig.12 It is a quantitative analysis of the relative fluorescence intensity of intracellular TNF-α, iNOS, NRF2, and HO-1.

[0034] Fig.13 Immunofluorescence staining images and three-dimensional statistical graphs of TNF-α, iNOS, NRF2, and HO-1 expression in chondrocytes after different treatments (red: detected protein; blue: cell nucleus; green: cytoskeleton. Scale bar: 20 μm).

[0035] Fig.14The protein expression levels of MMP3 / 9 / 13, SOX-9, PCNA and collageⅡ were analyzed semi-quantitatively. Blot lanes: 1. control group; 2. IL-1β group; 3. IL-1β+siRNA group (si); 4. IL-1β+TDN group (T); 5. IL-1β+Tsi group (Tsi).

[0036] Fig.15 Schematic diagram of the interaction of Tsi with inflammatory factors, matrix metalloproteinases, etc. in chondrocytes.

[0037] Fig.16 This is a heat map of the relative mRNA expression of MMP3 / 9 / 13, SOX-9, PCNA, and collagen.

[0038] Fig.17 It is a semi-quantitative analysis of the relative fluorescence intensity of MMP13, SOX-9, PCNA and collagenⅡ expression in cell immunofluorescence.

[0039] Fig.18 Immunofluorescence staining images and three-dimensional statistical graphs of MMP13, SOX-9, PCNA, and collagenⅡ expression in chondrocytes after different treatments. (Red: detection protein; blue: cell nucleus; green: cytoskeleton. Scale bar: 20μm)

[0040] Fig.19 Schematic diagram of the method and time of in vivo drug injection and animal sampling time.

[0041] Fig. 20 3D reconstruction of the subchondral bone region of the rat temporomandibular joint at 4 and 8 weeks after different treatments.

[0042] Fig.21 Quantitative analysis of trabecular parameters (relative bone volume (BV / TV), trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular space (Tb.Sp)) in the subchondral bone region of the temporomandibular joint of rats after different treatments at 4 and 8 weeks.

[0043] Fig. 22 After the injection of simple siRNA and Tsi into the joint cavity of rats with TMJOA or normal rats, the distribution and metabolism of Cy5-labeled siRNA were observed after 0, 15, 30, 45, 60, 90, 120, and 180 minutes.

[0044] Fig.23HE, Masson, Safranin O, and Col-Ⅱ staining images of the temporomandibular joints of rats at 4 and 8 weeks after treatment in different groups (scale bar: 200 μm), as well as quantitative statistics of articular cartilage thickness, OARIS score, and Mankin score.

[0045] Fig.24 The NF-κB, TNF-α, PCNA, and Tunel staining images of the temporomandibular joints of rats at 4 and 8 weeks after treatment in different groups (scale bar: 200 μm) and quantitative statistics.

[0046] Data are expressed as mean ± standard deviation (SD) (n = 3). Statistical analysis: one-tail < 0.05, two-tail < 0.01, three-tail < 0.001. * indicates "compared with IL-1β group", # indicates "compared with Tsi group". DETAILED DESCRIPTION

[0047] In the following examples and experimental examples, reagents and raw materials not specifically described are all commercially available products.

[0048] Example 1 Functionalized tetrahedral framework nucleic acid and preparation method thereof

[0049] This embodiment provides a tetrahedral framework nucleic acid system, Tsi, which is combined with siRNA related to silencing NF-κBp65 gene; it is based on base complementarity and is assembled by combining four pre-designed ssDNA sequences (sS1, sS2, sS3, sS4) with DNA sticky ends with the siRNA-NF-κB p65 sticky ends.

[0050] The nucleotide sequence of the single-stranded DNA sS1 is shown in SEQ ID NO.1: TTGACCTGTGAATTATTTATCACCCGCCATAGTAGACGTATCACCAGG CAGTTGAGACGAACATTCCTAAGTCTGAA;

[0051] The nucleotide sequence of single-stranded DNA sS2 is shown in SEQ ID NO.2:

[0052] TTGACCTGTGAATTACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG;

[0053] The nucleotide sequence of single-stranded DNA sS3 is shown in SEQ ID NO.3:

[0054] TTGACCTGTGAATTACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC;

[0055] The nucleotide sequence of single-stranded DNA sS4 is shown in SEQ ID NO.4:

[0056] TTGACCTGTGAATTACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG;

[0057] siRNA-NF-κB p65 nucleotide sequence:

[0058] sense(5'-3')GCGACAAGGUGCAGAAAGA(SEQ ID NO.5)dTdT;

[0059] antisense(5'-3')UCUUUCUGCACCUUGUCGC(SEQ ID NO. 6)dTdT.

[0060] The preparation method is as follows: four specially designed ssDNAs (S1, S2, sS3, S4) are added to TM buffer (10 mm Tris base, 50 m MgCl2, pH 8.0), vortexed and centrifuged, heated to 95°C for 10 minutes in a thermal cycler, cooled to 4°C for 20 minutes, and ssDNA self-assembles into tFNA according to the principle of base complementary pairing. Then siRNA and tFNA (1:1) are mixed and incubated at 37°C for 1 hour to prepare Tsi.

[0061] Comparative Example 1

[0062] This comparative example provides the control samples used in the experiment:

[0063] 1. tFNA

[0064] The sample is assembled by assembling four pre-designed ssDNAs (sS1, sS2, sS3, sS4) that are not bound to siRNA-NF-κB p65 based on base complementarity. The preparation method is the same as that in Example 1, wherein the nucleotide sequence of the single-stranded DNA sS1 is shown in SEQ ID NO.1: TTGACCTGTGAATTATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA

[0065] The nucleotide sequence of single-stranded DNA sS2 is shown in SEQ ID NO.2:

[0066] TTGACCTGTGAATTACATGCGAGGGTCCAATACCGACGATTACAGCTT

[0067] GCTACACGATTCAGACTTAGGAATGTTCG

[0068] The nucleotide sequence of single-stranded DNA sS3 is shown in SEQ ID NO.3:

[0069] TTGACCTGTGAATTACTACTATGGCGGGTGATAAAACGTGTAGCAAGC

[0070] TGTAATCGACGGGAAGAGCATGCCCATCC

[0071] The nucleotide sequence of single-stranded DNA sS4 is shown in SEQ ID NO.4:

[0072] TTGACCTGTGAATTACGGTATTGGACCCTCGCATGACTCAACTGCCTG

[0073] GTGATACGAGGATGGGCATGCTCTTCCCG

[0074] 2. siRNA

[0075] This sample is siRNA that silences the NF-κBp65 gene.

[0076] The siRNA-NF-κB p65 nucleotide sequence is as follows:

[0077] sense(5'-3')GCGACAAGGUGCAGAAAGA(SEQ ID NO.5)dTdT; antisense(5'-3')UCUUUCUGCACCUUGUCGC(SEQ ID NO.6)dTdT.

[0078] The technical solution of the present invention is further illustrated by experiments below.

[0079] Experimental Example 1 Characterization of Tsi Nanostructures

[0080] This experimental example characterizes the Tsi nanostructure prepared in Example 1.

[0081] 1. Experimental Methods

[0082] The successful preparation of tFNA and Tsi was confirmed by GelRed-stained agarose gel (2%) electrophoresis (AGE) (120 V, 30 min) and high-performance capillary electrophoresis (HPCE). The morphology and size of tFNA and Tsi nanomaterials were detected by atomic force microscopy (AFM) (Shimadzu, Kyoto, Japan) and transmission electron microscopy (TEM) (HT770, Hitachi, Japan). The size and zeta potential of tFNA and Tsi nanostructures were measured in ZetasizerNano (ZS90, Malvern, UK).

[0083] 2. Experimental Results

[0084] As shown in the gel image, in order to visually confirm the synthesis of Tsi, siR was labeled with Cy5, and the co-localization of Cy5 fluorescence (red) and tFNA fluorescence (blue) confirmed that siR was successfully loaded onto tFNA, thereby generating purple ( Figure 1 , B). Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used to observe the synthesized Tsi, showing that the tetrahedrons were triangular structures with sharp edges and were uniformly distributed in the solution ( Figure 1 C, D). Zeta potential and particle size of tFNA and Tsi were determined by dynamic light scattering (DLS) measurements ( Figure 1 E, F). Both tFNA and Tsi are negatively charged, with zeta potentials of -7.72±3.97 mV and -11.84±0.51 mV, and sizes of 8.31±0.81 nm and 12.35±0.89 nm, respectively. They are small in size and negatively charged, ensuring efficient uptake by cells.

[0085] Tsi was incubated in 2% serum to simulate the serum concentration of Tsi used in subsequent in vitro experiments, and the degree of siRNA degradation was determined based on its fluorescence intensity ( Figure 1 G). The results showed that Tsi maintained a strong fluorescence band at 24h, which showed good structural stability. We observed that T and Tsi could detect fluorescence bands at 0, 2, 3, 4, 5, 6, and 7 days in TM buffer at 4°C, and siRNA was rarely separated and almost not degraded. In summary, Tsi has a protective effect on siRNA degradation, laying the foundation for the effective delivery of siRNA to cells to achieve gene silencing.

[0086] Immunofluorescence and flow cytometry were used to evaluate the cell membrane permeability of Tsi (12 and 24 hours). In confocal microscopy, almost no fluorescence was observed in the siRNA group at 12 and 24 hours ( Figure 1J, K), the cellular uptake of siRNA by chondrocytes was extremely poor. However, the endocytosis of tFNA (250nM) and Tsi (250nM) was very significant. Flow cytometry also confirmed that Tsi significantly enhanced the uptake of siRNA by cells in a time-dependent manner, with the uptake of 12 and 24 cells reaching 43.1% and 76.9%, respectively, which was much higher than the 25.4% and 43.9% of the siRNA group alone ( Figure 1 H, I).

[0087] The above experimental results demonstrate the excellent ability of Tsi nanostructures as siRNA therapeutic carriers, showing great potential in maintaining siRNA stability and enhancing its cellular uptake ability.

[0088] Experimental Example 2: In vitro study of the therapeutic effect and regulatory mechanism of Tsi on temporomandibular arthritis

[0089] The siRNA, tFNA and Tsi samples used in this experimental example were prepared according to the method of Example 1 or Comparative Example 1.

[0090] 1. Experimental Methods

[0091] 1. Extraction and culture of temporomandibular joint chondrocytes

[0092] All procedures strictly followed the requirements of the governing ethical principles and were reviewed and approved by the Institutional Review Board of Sichuan University. Chondrocytes were extracted from the temporomandibular joint cartilage of newborn Sprague-Dawley rats. After the articular surface cartilage was sheared, the tissue was washed three times with phosphate-buffered saline (PBS) and digested in 0.25% (w / v) trypsin containing EDTA at 37°C for 30 min and 0.2% (w / v) type II collagenase at 37°C for 2 h. The cartilage tissue fragments were centrifuged (1000 rpm, 10 minutes) and resuspended in freshly prepared DMEM medium. All cell cultures were cultured in T25 culture flasks placed in a cell culture incubator (5% CO2, 37°C), and chondrocytes from passages 1 to 4 were used.

[0093] 2. CCK8

[0094] Cells were seeded in 96-well plates and subsequently stimulated with siRNA, tFNAs, or Tsi for 24 h under inflammatory conditions. After incubation with CCK-8 solution for 90 min, cell viability was assessed by measuring the OD value at 450 nm.

[0095] 3. IL-1β-induced in vitro temporomandibular inflammation model and grouping

[0096] Chondrocytes were stimulated with 10 ng / ml interleukin (IL-1β) for 24 hours. After inflammatory stimulation, in the treatment group, cells were starved with 2% FBS for 2 hours. Rat chondrocytes were then treated with 250 nmol siRNA, tFNA or Tsi for 24 hours. In the control group, chondrocytes were not treated.

[0097] 4. Uptake of siRNA, tFNAs or Tsi by chondrocytes.

[0098] Chondrocytes seeded on confocal culture dishes were cultured with IL-1β for 24 hours to induce an in vitro inflammatory model, while normal chondrocytes were not treated. Chondrocytes were treated according to the above treatment method in each group of materials. After rinsing the chondrocytes with PBS, the cells were digested and collected by centrifugation with EDTA-free trypsin, and the uptake of siRNA, tFNAs or Tsi by cells was detected by flow cytometry (CytoFlex, Beckman Coulter, USA). Chondrocytes treated with each group of materials were fixed with 4% paraformaldehyde, and the nuclei were stained with DAPI and the cytoplasm was stained with fluorescein isothiocyanate (FITC)-labeled phalloidin, and observed directly under a confocal microscope (Olympus, FV3000, Japan).

[0099] 5. Scratch closure test

[0100] 6. RT-qPCR

[0101] 7. Western Blotting

[0102] 8. Cell Immunofluorescence

[0103] 9. ROS detection and determination

[0104] Reactive oxygen species detection kit (Beyotime, S0033S, China) was used to measure the level of ROS induced by IL-1β. Cells were incubated with DCFH-DA solution (1:1000) for 20 min and Hoechst 33342 solution (1:1000) for 10 min. Fluorescence microscopy was used to capture intracellular ROS images.

[0105] 2. Experimental Results

[0106] 1. Tsi inhibits inflammation, promotes cell proliferation and resists apoptosis by silencing NF-κB p65

[0107] CCK-8 method was used to evaluate the effects of siRNA, tFNA and Tsi (250nM) on chondrocyte viability. The results showed that tFNA and Tsi could slightly enhance the proliferation of IL-1β-injured chondrocytes ( Figure 3). The results of the scratch closure test showed that the proliferation ability of CH cells was inhibited in the presence of IL-1β. Among them, the improvement effect of simple siRNA was very small compared with the IL-1β group. In the 6th and 12th hours of the scratch, the CH cell closure of the Tsi group reached nearly twice that of IL-1β. In the 24th hour, the improvement effect was still obvious compared with that of IL-1β, greatly promoting the proliferation and migration of chondrocytes ( Figure 2 ).

[0108] Flow cytometry results showed that under the condition that IL-1β greatly promoted chondrocyte apoptosis, siRNA alone had only a certain protective effect on chondrocyte apoptosis. However, tFNA and Tsi could more effectively inhibit chondrocyte apoptosis, among which Tsi had the strongest inhibitory effect ( Figure 4 ).

[0109] RT-QPCR was used to detect the silencing efficiency of simple siRNA and Tsi on NF-κBp65 signaling. The results showed that at the first day, under inflammatory conditions, the NF-κB gene increased to 10 times that of the non-inflammatory control group. After treatment with simple siRNA, the target gene expression decreased to 4.5 times that of the control group, while after treatment with Tsi, the target gene expression decreased to 2.5 times that of the control group, which was much lower than the expression level of the inflammatory group. After 3 days, the target gene had increased to 7.5 times that of the control group in the treatment containing simple siRNA. However, NF-κB in the Tsi transfection group still remained at a low level. This proves the sustained effect of the Tsi system on carrying siRNA and the good target gene silencing effect. ( Figure 3 )

[0110] Western blotting experiments also proved that IL-1β stimulation significantly upregulated the expression of NF-κB p65 and NF-κB p-p65 in chondrocytes, and IκB-α decreased significantly, resulting in aggravated inflammation. Both tFNA and Tsi significantly downregulated the expression of NF-κB and its phosphorylation products, and upregulated IκB-α, among which the effect of Tsi was the most significant. Cell immunofluorescence also verified this trend. This result further confirmed that Tsi has excellent siRNA delivery and protection functions through effective entry into cells and accurate gene silencing, reversing the activation effect of IL-1β stimulation on NF-κB and its downstream pathways.

[0111] In the Western blot experiment, β-catenin in chondrocytes induced by IL-1β was significantly enhanced compared with the control group. tFNA and Tsi reduced the expression level of β-catenin in chondrocytes, which was consistent with the effect of silencing NF-κB, among which Tsi had the most significant effect. The above results indicate that Tsi can also protect chondrocytes by inhibiting the Wnt / β-catenin signaling pathway. ( Figure 2 )

[0112] The above experimental results prove that Tsi inhibits inflammation by silencing NF-κB p65, promoting cell proliferation and anti-apoptosis, and inhibiting the Wnt / β-catenin signaling pathway to protect chondrocytes, thereby treating temporomandibular inflammation.

[0113] 2. Tsi promotes the NRF2 / OH-1 pathway, reduces ROS, and reduces cellular oxidative stress

[0114] Immunofluorescence detection of intracellular ROS levels ( Fig.10 ), and untreated chondrocytes were used as controls. Compared with the control group, the production of ROS in chondrocytes was significantly upregulated after IL-1β treatment. In contrast, tFNA and Tsi treatment significantly reduced the production of ROS, among which Tsi had the strongest effect.

[0115] Western blot analysis and immunofluorescence were used to detect the expression of NRF2 and HO-1 in rat chondrocytes stimulated by IL-1β. The results showed that under IL-1β stimulation, Tsi treatment significantly increased the protein levels of NRF2 and HO-1, and tFNA also had a significant effect on increasing the expression of NRF2 and HO-1 ( Figure 8 ); Immunofluorescence and gene quantification also follow this trend ( Fig.12 , 13). Therefore, Tsi has the effect of resisting oxidative stress.

[0116] Western blot analysis and immunofluorescence staining showed that under IL-1β stimulation, TNF-α and IL-1β in chondrocytes were greatly increased, and iNOS also increased significantly. tFNA treatment significantly downregulated the expression levels of the above inflammatory factors in chondrocytes. After siRNA treatment, the expression levels of TNFα and iNOS were consistent with those of the tFNA group, but the downregulation of IL-1β was not very obvious. Among them, the effect of Tsi was very significant, reaching the level of the control group or even lower. Gene levels were detected by RT-PCR. After IL-1β stimulation, the expression of TNF-α, IL-1β, and IL-6 genes increased significantly, and the tFNA and siRNA groups could slightly inhibit the increase of related genes. However, compared with other groups, the anti-inflammatory effect of Tsi was significantly improved. This shows that Tsi has better anti-inflammatory properties.

[0117] The above experimental results prove that Tsi has anti-inflammatory and antioxidant effects, and improves temporomandibular joint inflammation by promoting the NRF2 / OH-1 pathway.

[0118] 3. Tsi reduces the production of matrix metalloproteinases and promotes cartilage matrix production

[0119] Western blot analysis results Fig.14As shown in the figure, compared with the control group, the production of catabolic enzymes (MMP3 / 9 / 13) was significantly upregulated after IL-1β induction, and the reversal of the extracellular matrix destruction caused by IL-1β was observed in chondrocytes treated with tFNA and Tsi. Tsi had the most significant effect and showed the strongest inhibitory effect, while siRNA was not obvious. Protein level ( Fig.14 ) and mRNA levels ( Fig.16 )The results are consistent.

[0120] The expression of cartilage proliferation-related genes (including PCNA and SOX9) and an important component of the cartilage extracellular matrix (COL-II) was further determined. The gene expression of PCNA and SOX9 in the siRNA, tFNA, and Tsi groups was higher than that in the IL-1β group. Compared with the other experimental groups, Tsi had the greatest promoting effect ( Fig.16 ). Western blotting ( Fig.14 ) and immunofluorescence staining ( Fig.18 ) were studied and, consistent with the RT-qPCR results, the protein secretion of COL-II in chondrocytes stimulated with IL-1β was upregulated after treatment with the above-mentioned nanodrugs (especially Tsi).

[0121] The above experimental results show that Tsi exhibits more prominent cartilage protective properties.

[0122] Experimental Example 3: Investigating the therapeutic effect and regulatory mechanism of Tsi on temporomandibular arthritis at the in vivo level

[0123] The siRNA, tFNA and Tsi samples used in this experimental example were prepared according to the method of Example 1 or Comparative Example 1.

[0124] 1. Experimental Methods

[0125] 1. Establishment of TMJOA animal model

[0126] Animal experiments were conducted in accordance with the guidance of the Animal Ethics Committee of the West China School of Stomatology, Sichuan University. Rats were randomly divided into five groups (sham operation group, OA group, siRNA group, tFNA group and Tsi group) (6 weeks old) and randomly divided into 5 groups (n=6). After 7 days of adaptation, except for the sham operation group, 30ul of type II collagenase was injected into the supra-articular cavity of the bilateral temporomandibular joints of the rats using a 30-gauge needle. Type II collagenase induced sustained inflammation and increased expression of proinflammatory cytokines, leading to TMJOA-like changes and inducing a TMJOA model. Two weeks after TMJOA induction, rats were injected with 30ul of siRNA, tFNA and Tsi intra-articularly on both sides once a week for 4 and 8 weeks ( Figure 1C). Rats in the sham operation group received only acupuncture instead of injection of type II collagenase and the materials of each group. Rats were housed at a controlled temperature with a 12-h light / dark cycle and were allowed to move freely and have access to food and water.

[0127] 2. Biodistribution in vivo

[0128] In order to observe the distribution of pure siRNA and Tsi drugs in vivo and the ability of Tsi to protect siRNA, siRNA was labeled with cy5 fluorescence and uniformly injected into the temporomandibular joint of rats. The distribution and degradation of drugs in the temporomandibular joint cavity of rats were examined by fluorescence imaging system (IVIS Lumina III series, PerkinElmer, USA) at different time points (1, 2, 3, 4, 5 days).

[0129] 3. Micro-CT analysis

[0130] At 4 and 8 weeks after treatment, the animals were euthanized and the bilateral temporomandibular joints were surgically removed. The dissected temporomandibular joint condyles were fixed in 10% (v / v) neutral buffered formalin (pH 7.4) for 2 days and scanned by micro-CTscanner (45μCT; SCANCO Medical, Switzerland). The samples were scanned coronally at 55kV and 100μA with an effective pixel size of 10μm. Sagittal and apical images of the condyles were reconstructed. The percentage of bone volume to total volume (BV / TV, %), trabecular thickness (Tb·Th, mm), trabecular separation (Tb.Sp, mm), and trabecular number (Tb·N, 1 / mm) were subsequently analyzed.

[0131] 4. Histological analysis

[0132] After micro-CT examination, the fixed TMJ specimens were decalcified in formalin-EDTA. Subsequently, all samples were dehydrated in ethanol gradient. After embedding in paraffin, serial sections were cut. The condylar cartilage was stained with H&E, Masson, and Safranin-O to obtain the general morphology of the condylar cartilage. Immunohistochemical staining was then performed to detect indicators such as nfkb and PCNA. According to the stained sections, the quality of joint repair was evaluated by 3 blinded independent observers using the Mankin histological scoring system and OARIS score, and the thickness of articular cartilage was determined. For semiquantitative analysis of the expression levels of nfkb, PCNA, and Tnfα, the positively stained cells were counted at 200× magnification in three fields of view and expressed as the percentage of positive cells. All samples were stained using TUNEL staining (Roche, Mannheim, Germany) and chondrocyte apoptosis in different groups was analyzed. For immunofluorescence analysis, an important protein in cartilage (COL-II) was stained to estimate the recovery rate of OA.

[0133] 5. Statistical analysis

[0134] All experimental analyses in this study were performed independently at least three times. Experimental data are expressed as standard deviation ± mean. All experimental data were recorded and analyzed using ImageJ and GraphPad Prism software version 9 (San Diego, USA). Data are expressed as mean ± standard deviation. Group differences were compared using one-way analysis of variance (ANOVA) followed by Tukey's multiple test correction. Here, p < 0.05, p < 0.01, and p < 0.001 were considered statistically significant.

[0135] 2. Experimental Results

[0136] 1. Tsi's silencing efficiency of NF-κB in the temporomandibular joint cartilage of TMJOA rats and its protective effect on the joint

[0137] The temporomandibular joint region was imaged and acquired using an in vivo imaging system (IVIS) at seven different time points. Fig. 22), at all time points, in the healthy group and TMJOA group, the fluorescence intensity of the Tsi-injected joints was significantly higher than that of free siRNA, indicating that Tsi effectively enhanced the stability of siRNA and prolonged its effective interaction time. In arthritic rats, the Tsi group had better retention in the first 30 minutes, and the fluorescence intensity did not decrease significantly. It began to decrease significantly in the 30-45 minutes, and still had fluorescence intensity after 180 minutes, indicating that Tsi's action time in the joints can reach 180 minutes. Compared with simple siRNA, it has a longer time and more effective concentration of protective effects on the joints. In the joint cavity of the healthy group, Tsi also decreased more slowly, but the retention rate was lower than that of the OA group, indicating that the inflammatory microenvironment of TMJOA would increase the retention effect of Tsi. The experiment showed that Tsi effectively promoted the retention of siRNA in the joint cavity in temporomandibular arthritis.

[0138] Micro-computed tomography (microCT) was used to examine the changes in the subchondral bone of the temporomandibular joint of rats, and the region of interest was selected for three-dimensional reconstruction and observed from top view to sagittal view ( Fig. 20 ) and analyzed its bone-related parameters (i.e., the percentage of bone volume to total volume (BV / TV), trabecular thickness (Tb·Th), trabecular separation (Tb.Sp) and trabecular number (Tb·N)) and three-dimensional structure. After 4 weeks of tFNA treatment, BV / TV increased by 19.6% (P < 0.05) and Tb·Th increased by 0.11mm (P < 0.01) compared with the OA group, and bone loss was weakened. However, the other two parameters Tb.Sp and Tb·N ( Fig.21 ) There was no statistically significant difference. Compared with the OA group, the BV / TV and Tb·Th of the OA+Tsi group were 77.5% (P=0.011) and 0.28mm, respectively, and the Tb.Sp was 0.09mm, which were significantly different from the OA group, and the trend was consistent at week 8. The four bone structure parameters of the siRNA-only treatment group were comparable to those of OA, indicating that Tsi has a stronger protective effect on subchondral bone than siRNA and TFNA alone.

[0139] From HE staining, it was known that in the OA group, over time, the condylar surface showed cartilage damage, the joint surface was not smooth, the cartilage layer thickness became thinner, the cell structure was disordered, and a large amount of cartilage collagen was lost. The Tsi group significantly promoted the repair of inflammation-induced ECM loss, the continuity of the condylar surface increased, and the thickness of the condylar cartilage (especially the thickness of the mature layer + hypertrophic layer) increased. Masson staining can reflect the level of glycosaminoglycans in cartilage. It was observed that the OA group had a large amount of ECM degradation at 8 weeks, and glycosaminoglycans decreased significantly. Tsi can reverse this effect. ( Fig.23 )

[0140] The OARSI grade is a semi-quantitative scoring scale for OA. The Mankin score is a cartilage damage grading system based on tissue morphology. The higher the scores of these two, the more severe the damage to the temporomandibular joint and cartilage. From the experimental data, after treatment with siRNA, tFNA and Tsi, cartilage regeneration was observed, the synovium was thicker, the articular cartilage was more complete, and the cartilage surface was arranged smoothly and orderly, so the OARSI grade and Mankin score were low ( Fig.23 ).

[0141] Taken together, these observations suggest that Tsi alleviates tissue damage and / or enhances tissue repair in the TMJO, effectively inhibits the loss of cartilage collagen, maintains cartilage integrity, and attenuates the development of TMJOA.

[0142] 2. Tsi silences NF-κB in rat temporomandibular joints, fights inflammation and promotes cartilage matrix production

[0143] According to Safranin-O staining analysis, the red staining area of ​​the Tsi group was much higher than that of the other treatment groups at each period, and the degree of protection of the cartilage matrix was very good ( Fig.23 Representative images of TUNEL staining of the medial side of the temporomandibular joint showed that the number of apoptotic chondrocytes in the OA group increased at 4 and 8 weeks ( Fig.24 siRNA, tFNAs, and Tsi can reduce the number of apoptotic chondrocytes, especially Tsi. Immunofluorescence was used for evaluation. Representative images at 4 and 8 weeks are shown ( Fig.23 ), the fluorescence intensity of COL-II in the OA group decreased sharply compared with the control group. After siRNA, tFNAs, and Tsi treatment, the content of COL-II in the synovium and articular cartilage increased to varying degrees. The results showed that Tsi significantly attenuated the occurrence of OA by inhibiting chondrocyte apoptosis, smoothing the cartilage surface, inhibiting ECM degradation, and increasing synovial thickness, thereby effectively and efficiently protecting articular cartilage.

[0144] The histochemical results showed that NF-κB Fig.24 ), the targeted silencing effect of Tsi on NF-κB in TMJOA was much higher than that of the simple siRNA group both in the early and late stages, proving the high efficiency of the tetrahedral nucleic acid framework as a carrier of siRNA in tissue penetration and entry into cells and targeted silencing of genes.

[0145] The results of immunohistochemistry showed that at week 4, the expression of TNF-α in the OA group was significantly higher than that in the control group, while PCNA was decreased. The expression levels of TNF-α in the siRNA and tFNA groups were significantly lower than those in the OA group. However, there was no significant difference in PCNA expression between the OA group and the OA group ( Fig.24). The percentage of PCNA cells in the Tsi group was higher than that in the OA group, with a statistically significant difference (P < 0.001). At the 8th week of temporomandibular arthritis, the difference in TNF-α and PCNA between the OA and control groups was very obvious. Compared with the OA group, Tsi reduced the level of TNF-α. PCNA showed an opposite trend to the above. In the Tsi group, the number of PCNA-positive cells increased greatly, which was higher than that in the OA group, indicating that Tsi played a great role in inhibiting the release of matrix metalloproteinases and promoting cartilage proliferation.

[0146] The above in vivo experiments prove that the tetrahedral nucleic acid framework as a carrier of siRNA has high efficiency in targeted gene silencing and can treat temporomandibular arthritis from multiple angles.

[0147] In the above experiments, compared with simple siRNA, Tsi has excellent performance in inhibiting pro-inflammatory factors such as TNF-α and iNOS, reducing MMP, reducing cell apoptosis, promoting cell proliferation and protecting the degradation of cartilage matrix, playing a multi-faceted and full-process protective role in the occurrence and development of temporomandibular arthritis.

[0148] Therefore, in general, the construction of this siRNA-carrying Tsi delivery system provides new opportunities and methods for the anti-inflammatory and proliferative treatment of clinical temporomandibular arthritis, and has extremely bright prospects and huge clinical potential.

Claims

1. A functionalized tetrahedral framework nucleic acid, characterized in that: The functionalized tetrahedral framework nucleic acid is modified with siRNA-NF-κB p65.

2. The functionalized tetrahedral framework nucleic acid according to claim 1, characterized in that: It combines four single-stranded DNAs with sticky ends with the sticky ends of siRNA-NF-κB p65 to form a DNA-siRNA chain, and assembles the four DNA-siRNA chains through complementary base pairing.

3. The functionalized tetrahedral framework nucleic acid according to claim 2, characterized in that: The 4 single-stranded DNA nucleotide sequences are shown as SEQ ID NO.1-SEQ ID NO.4; And / or, the sense strand of siRNA-NF-κB p65 is the nucleotide sequence shown in SEQ ID NO.5 having two deoxynucleotides at the 3' end.

4. The method for preparing the functionalized tetrahedral framework nucleic acid according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: mixing siRNA-NF-κB p65 and four pre-designed single-stranded DNAs, and incubating them to obtain the result.

5. Use of the functionalized tetrahedral framework nucleic acid according to any one of claims 1 to 3 in the treatment of temporomandibular arthritis.

6. The use according to claim 5, characterized in that: The drug is used to protect chondrocytes.

7. The use according to claim 5, characterized in that: The medicament is used to reduce cellular oxidative stress.

8. The use according to claim 5, characterized in that: The drug is used for promoting cartilage matrix production.

9. The use according to claim 5, characterized in that: The drug is used to inhibit chondrocyte apoptosis, smooth cartilage surface, inhibit extracellular matrix degradation and increase synovial membrane thickness to significantly attenuate the occurrence of osteoarthritis.

10. A drug for treating temporomandibular arthritis, characterized in that: The invention is prepared by taking the functionalized tetrahedral framework nucleic acid as any one of claims 1 to 3 as an active ingredient and adding pharmaceutically acceptable auxiliary materials.